Le Lézard
Classified in: Health, Science and technology
Subject: Funding

Bioventus Makes $15 Million Equity Investment in CartiHeal with an Agreed Option Structure to Acquire Company Upon Milestone Achievements


CartiHeal, developer of the proprietary Agilitm-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, has secured an additional $15 million equity investment from Bioventus, a global leader in orthobiologics. The investment follows the recently completed enrollment and outcome of interim analysis in CartilHeal's investigational device exemption (IDE) multinational pivotal study. An additional $5 million can be secured by CartiHeal from Bioventus, if needed, for IDE study completion.

This new round of funding is expected to enable CartiHeal to complete all patient follow-up in the study and submit a first application for premarket approval (PMA) to the FDA. Bioventus made an initial $2.5 million investment in the Agili-C IDE study in January 2018, as part of a previous financing round.

Bioventus and CartiHeal have agreed on an option structure under which Bioventus will acquire the company shortly after FDA approval of the Agili-C implant. Terms of that option structure are not disclosed.

"We are pleased Bioventus continues to see value in the Agili-C implant and is making a greater investment to support the completion of the IDE study," said Nir Altschuler, founder & CEO, CartiHeal. "We look forward to the work ahead and a successful application for PMA approval."

"The successful enrollment and outcome at the interim analysis of CartiHeal's pivotal study for Agili-C implant is an important milestone," said Ken Reali, CEO, Bioventus. "It is a testament to the strength of its continuing development program and more importantly the future potential of the Agili-C technology in addressing the large unmet need in patients with joint surface lesions. This investment underscores our belief in the novel technology and we look forward to working with the team at CartiHeal in the years to come."

Credit Suisse is acting as financial advisor to CartiHeal.

About CartiHeal

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.

About the Agili-C implant IDE multinational pivotal study

The trial's objective is to demonstrate the superiority of the Agili-C implant over the surgical standard of care (microfracture and debridement) for the treatment of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative changes. It includes more than 250 patients in centers in the US, Europe and Israel.

About Bioventus

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, www.bioventus.com and follow the company on LinkedIn and Twitter.

Bioventus and the Bioventus logo are registered trademarks of Bioventus, LLC.


These press releases may also interest you

at 00:15
UAE-based eyewear e-commerce player eyewa, has raised a pre-series B bridge round of US$2.5million from Wamda Capital, EQ2 Ventures and Nuwa Capital. This is eyewa's third funding round, it comes hard-on-the-heels of a mid-2019 Series A round of...

at 00:01
Coca-Cola European Partners (CCEP), the world's largest Coca-Cola bottler based on revenue, has signed a multiyear agreement with IBM to accelerate its transformation to an open hybrid cloud...

at 00:00
Genomenon announced today that CEO Mike Klein has been named to TechCEOs list of "Top 25 Biotechnology CEOs of 2020". Klein was recognized for leading Genomenon, one of the most innovative health IT companies in genomics. Genomenon's AI-powered...

at 00:00
Implementing the IMDRF Codes: Essential Adverse Event Reporting Changes An FDAnews Webinar Thursday, Aug. 20, 2020, 1:30 p.m.-3:00 p.m. EDT https://www.fdanews.com/imdrfcodes Beginning September 7, the FDA will require devicemakers to use a new...

10 aoû 2020
Total (China) Investment (the Company) has signed a Memorandum of Understanding (MoU) in order to pursue strategic collaboration with Alibaba Group ("Alibaba") and leverage their respective resources to drive the digital transformation of the...

10 aoû 2020
Issued by: AU Optronics Corp. Issued on: August 10, 2020 Hsinchu, Taiwan, August 10, 2020? At the Display Week 2020 online exhibition, Dr. Frank Ko, AUO President and Chief Operating Officer, delivered an online keynote speech titled "Display...



News published on 16 july 2020 at 09:25 and distributed by: